Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. Methods In a 71-week, double-blind, randomized, placebo-controlled trial conducted at 22 sites in four countries, we enrolled persons without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obesity-related complication. The participants were randomly assigned in a 2:1 ratio to receive oral semaglutide (25 mg) or placebo once daily, plus lifestyle interventions. The coprimary end points at week 64 were the percent change in body weight and a reduction of 5% or more in body weight; confirmatory secondary end points included reductions in body weight of 10% or more, 15% or more, and 20% or more and the change in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score. Results A total of 205 participants were randomly assigned to receive oral semaglutide, and 102 to receive placebo. The estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group (estimated difference, -11.4 percentage points; 95% confidence interval, -13.9 to -9.0; P Conclusions Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More recently, oral semaglutide 25 mg has been shown to induce a 13.6% WL after 71 weeks in obese individuals with T2DM [141].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [141]
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationEuropean Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Global burden of obesity in 2005 and projections to 2030
Kelly, T., Yang, W., Chen, C.-S., Reynolds, K., & He, J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.102 · Cited by 3,319
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationTranscellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553
Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
Self-citationBoye, K., Ross, M., Mody, R., Konig, M., & Gelhorn, H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14244 · Cited by 88
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70
Cited by
Horn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02165-8 · Cited by 70
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
“Top line results for the EVOKE trials revealed no reduction in rates of cognitive decline in patients treated with semaglutide, despite evidence for improvement in Alzheimer’s disease-related biomarkers 54 .”
Sievenpiper, J. L., Ard, J. D., Blüher, M., Chen, W., Dixon, J. B., Fitch, A., Gigliotti, L., Khunti, K., Lecube, A., Lean, M., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100228 · Cited by 56
Survodutide Once Weekly for the Treatment of Adults with Obesity
le Roux, C. W., Wharton, S., Startseva, E., Kloer, I. M., Hussain, S. A., Unseld, A., Bozkurt, B., Ard, J. D., Bays, H. E., Bogdański, P., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600751 · Cited by 33
Self-citationThe evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“There are also data supporting benefits of several compounds, including semaglutide 17,281 , tirzepatide 282 , survodutide 164 , and retatrutide 283 , across multiple liver-related end points in MASH, with semaglutide currently the only agent among these to have received regulatory approval for MASH (accelerated FDA a…”
InfluentialØstergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
“%) with daily 25 mg oral semaglutide after 64 weeks [172].”
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“More recently, oral semaglutide 25 mg has been shown to induce a 13.6% WL after 71 weeks in obese individuals with T2DM [141].”
InfluentialOral Treatment of Obesity by GLP-1 and Its Analogs
Holler, N., Ruseska, I., Schachner-Nedherer, A.-L., Zimmer, A., & Petschacher, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121596 · Cited by 13
Podder, D., Stala, O., Miah, A., Agyapong, A., Moore, M. E., Hirani, R., Diegisser, D., Garcia, V. G., & Etienne, M. (2026) · Diabetology · doi:10.3390/diabetology7030046 · Cited by 19
Johnson, A. J., O’Sullivan, E. N., Valyasevi, P., Metras, B. N., Jang, S., Shields‐Cutler, R. R., Arlinghaus, K. R., Harindhanavudhi, T., & Teigen, L. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0219 · Cited by 11
From needles to pills: oral GLP-1 therapy enters the obesity arena
Santulli, G. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00245-5 · Cited by 12
“The new NEJM trials of oral orfor-glipron and high-dose oral semaglutide [1, 2] represent the closest we have come to that reality.”
Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies
Alhazmi, A., & le Roux, C. W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1788698 · Cited by 10
Niazi, S. K. (2026) · Frontiers in Drug Delivery · doi:10.3389/fddev.2026.1776167 · Cited by 8
Šantić, R., Martinovic, L., Pavlović, N., Rušić, D., Kumrić, M., Martinović, D., Kurir, T. T., & Božić, J. (2026) · Metabolites · doi:10.3390/metabo16060364 · Cited by 11
“…reproduced in complementary clinical settings, including adults with type 2 diabetes (STEP 2), weight-loss maintenance after run-in semaglutide exposure (STEP 4), longer-term follow-up over 104 weeks (STEP 5), and oral semaglutide obesity trials (OASIS 1 and later dose-ranging studies) [3,42–45].”
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff, A. M., Kaplan, L. M., Davies, M. J., Wilding, J. P. H., Ahmad, N. N., Murray, M. H., Du, Y., Makarova, N., Giblin, K. A., Schloot, N. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604169 · Cited by 9
Overgaard, R. V., Birkhan, O. A., Rathor, N., Sparsø, T., Strathe, A., Wharton, S., & Rubino, D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70769 · Cited by 9
“Additionally, when comparing the STEP 1 trial and OASIS 4 trial [7, 8], overall discontinuation rates were 7.0% and 6.9%, respectively, in the semaglutide treatment arms, indicating similar tolerability of the oral and s.c. formulations.”
InfluentialSelf-citationPolu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
Papapetropoulos, A., Topouzis, S., Alexander, S. P. H., Cortese-Krott, M. M., Helyes, Z., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri, R., Patel, H. H., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70376 · Cited by 5
“…novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html), based on a Phase III trial, in which semaglutide reduced body weight in overweight or obese participants with no diabetes by 13.6% compared to a reduction of 2.1% by placebo (Wharton et al., 2025).”
InfluentialPill version of obesity jab is approved in US, with UK decision pending
Dyer, O. (2026) · BMJ · doi:10.1136/bmj.s2 · Cited by 5
Qiao, W., Yang, L., Liu, Y., Zhang, H., Zheng, Z., Gu, T., Zhu, J., Hu, X., Li, G., Zhang, Y., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03859-0 · Cited by 4
Forzano, I., Narciso, V., Canonico, M. E., Castiello, D. S., Florimonte, D., Manzi, L., Semplice, F., Vallone, D. M., Cristiano, S., Spinelli, A. M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031108 · Cited by 5
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Huerta, M., Muraoka, N., Jensen, M. B., Kartha, V. K., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag732 · Cited by 4
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
Li, M., Fang, J., Qi, G., Guo, S., Xu, T., Lu, Y., Yuan, Q., Wang, J., Zhu, S., Shen, J., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00077 · Cited by 3
Michalak, W., Bøg, M., Bendixen, T., Chowdhury, R., Cowley, P., Laugesen, C., Rathor, N., & Kushner, R. F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70919 · Cited by 4
Mora, P., Aroda, V. R., Asong, M., Blüher, M., Carlander, A. F., Kaltoft, M., Vilsen, L. N., & Rosenstock, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01247-x · Cited by 4
Yue, D., Hua, X., Zhu, L., Wang, J., Gu, L., Yuan, Z., Jian, W., Chen, Y., & Meng, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1684395 · Cited by 2
Saeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
“Additionally oral semaglutide has also been investigated for chronic weight management in the OASIS program (details beyond the scope of this review) with oral semaglutide 25 mg dose now been submitted to the FDA for approval for this indication [19, 20].”
Tom-Ayegunle, K., Tom-Ayegunle, O., Okoye, S., Chukwuemeka, U., Adeyina, T., Babarinde, A. O., & Eleam, U. (2026) · Cureus · doi:10.7759/cureus.100947 · Cited by 5
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
“HbA1c decreased by 0.3% with semaglutide 25 mg daily compared to 0.1% with placebo [31].”
InfluentialKhachaturov, M., & Goulis, D. G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70822 · Cited by 3
“Recently, Novo Nordisk extended its semaglutide program with data from the OASIS 4 trial [10], showing that oral semaglutide 25 mg provides a clinically meaningful non-injectable option for obesity management.”
Zaman, W., & Amin, A. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2676109 · Cited by 2
“However, these findings should be interpreted cautiously because no definitive head-to-head trials have established equivalence or superiority versus semaglutide 2.4 mg in STEP 1, tirzepatide in SURMOUNT-1, or oral semaglutide 25 mg [25,53,54].”
InfluentialHamarsheh, S., Jaber, A. R., Abu-Khazneh, O., Andonie, C. R., Majadleh, S., Zahran, A., & Ayesh, H. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70248 · Cited by 2
“Semaglutide, a GLP-1 receptor agonist, is approved for weight management [7, 8].”
Kamrul-Hasan, A. B. M., Dutta, D., Mahajan, K., Nagendra, L., Pappachan, J. M., Bhattacharya, S., & Kalra, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70922 · Cited by 2
Plotkin, M., Ivkovic, M., Smith, I., Rathor, N., Chowdhury, R., Hodkinson, A., & Kushner, R. F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70911 · Cited by 2
“Oral semaglutide demonstrated benefits in reducing body weight in patients with obesity in the OASIS clinical trial programme [11–15].”
InfluentialAhmad, Y., Wasan, R., Perchik, J. D., & Nanda, N. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124430 · Cited by 2
“While the rate of gastrointestinal side effects was similar to that in a previous trial involving 50 mg oral semaglutide daily, there was a lower rate of dysesthesia with 25 mg oral semaglutide daily [119].”
Kassem, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71293 · Cited by 2
“Most events are mild to moderate, transient and occur during dose escalation [31].”
From Gila monster venom to dermatology: The history of glucagon-like peptide-1 receptor agonists
Dyson, S., Hoenig, L. J., & Levell, N. J. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.09.011 · Cited by 2
Meng, Y., Jin, T., Ren, L., Thompson, M. L., & Wang, Y. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0033 · Cited by 1
Seighali, N., Chahkand, M. S. G., Ebrahimzade, M., Arashlow, F. T., Maroufi, S. P., Rahnama, P., Matin, M. H., Javazm, A. K., Ebrahimi, P., Nasir, K., et al. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01149-5 · Cited by 2
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia
Malik, A., & Malik, R. A. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004250 · Cited by 1
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Lee, A.-H., & Holmes-Walker, D. J. (2026) · Healthcare · doi:10.3390/healthcare14060734 · Cited by 2
Ojinna, B. T., Tariq, S., Agho, O., Channa, R., & Singh, G. (2026) · Cureus · doi:10.7759/cureus.107970 · Cited by 4
Fadini, G. P., Morieri, M. L., Boscaro, C., Bonora, B. M., & Cignarella, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70840 · Cited by 1
“In the OASIS 1 and 4 [18, 19] and PIONEER PLUS studies [12], doses of 25 mg and 50 mg daily produced additional weight loss compared to the 14 mg dose, without a commensurate further reduction in HbA1c, illustrating the right-shifted nature of the dose–response for body weight.”
Nguyen, T., Hong, L., & Iso, T. (2026) · Cardiorenal Medicine · doi:10.1159/000552517 · Cited by 1
Lista, S., Ballerio, M., López‐Ortiz, S., Khoramipour, K., Imbimbo, B. P., Santos‐Lozano, A., Minoretti, P., & Emanuele, E. (2026) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2026.174217 · Cited by 1
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Jagtap, N., Golchha, A., Katrevula, A., Asif, S., Rughwani, H., Koduri, K. K., Balenki, P., Kalapala, R., & Reddy, D. N. (2026) · Endoscopy · doi:10.1055/a-2891-4165 · Cited by 1
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management
Rubino, D., Wharton, S., Knight, M. G., & Aroda, V. R. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2686467 · Cited by 1
“In OASIS 4, the most common GI disorders associated with oral semaglutide were nausea, affecting 47% of patients and lasting for a median 13 days (versus 19% and 12 days with placebo), and vomiting, reported by 31% of patients and lasting for a median 2 days (versus 6% and 1 day with placebo) [16].”
InfluentialSelf-citationOvergaard, R. V., Agersø, H., Hollensen, C., Rathor, N., & Bomberg, E. M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71030 · Cited by 1
“Although GLP-1 RA-based therapies are generally well tolerated with relatively low treatment discontinuation due to adverse events in clinical trials, discontinuation increases with higher doses [3, 5, 6].”
InfluentialMedical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Alhazmi, A., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71074 · Cited by 1
Fredholt, F., Raptis, K., Rønholt, S., Hofmann, M., Varum, F., Blaabjerg, L. I., & Nielsen, H. M. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127237 · Cited by 1
MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice
Li, S., Toutoungy, M., Patel, J., Bhavsar‐Burke, I., & VanWagner, L. B. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01380-9 · Cited by 2
“Higher-dose oral formulations achieve ~ 13.6–15.1% weight loss in the OASIS trials [ 69].”
InfluentialKamrul-Hasan, A. B. M., Ashraf, H., Nagendra, L., Khalil, I., Chatterjee, S., Dutta, D., Haq, T., Alanazi, M. A., & Pappachan, J. M. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70181 · Cited by 1
“In contrast, oral semaglutide (25–50 mg) showed a safety profile characterized by transient, mainly mild‐ to‐moderate gastrointestinal events that peaked during dose escalation, with infrequent serious adverse events occurring at rates similar to placebo [18–20, 39, 40].”
InfluentialFor Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
“However, previous clinical trials with higher doses of oral semaglutide, 25 mg and 50 mg, showed significantly greater weight loss than orforglipron at − 13.6% (64 weeks) and − 15.1% (68 weeks), respectively [31,133].”
InfluentialClinical translation of permeation enhancers
Janjua, T. I., Choi, J.-W., Ross, B. P., Gleeson, J. P., Mitragotri, S., & Popat, A. (2026) · Nature Reviews Materials · doi:10.1038/s41578-026-00954-y · Cited by 1
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Machado, L. G., Schmidt, P. H. S., Petroski, G. T., Costa, G. L. L., Ribeiro, L., da Cruz, J. V. R., Canto, G. D. L., Hohl, A., Ronsoni, M. F., & van de Sande‐Lee, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71432 · Cited by 2
Comparing benefits and harms of obesity drugs
Gasoyan, H., & Rothberg, M. B. (2026) · BMJ · doi:10.1136/bmj-2026-725349 · Cited by 1
Moiz, A., Filion, K. B., Samuels, A. E., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05519
Chakaroun, R. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01389-9
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight
Lee, H. M., Marakkalage, K. G., Kim, S. H., Lee, S., Lee, J. H., Park, H. S., & Yoo, S. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02161-9
Oral Semaglutide in Adults with Overweight or Obesity
Wharton, S., do Vale, R. D., & Garvey, W. T. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2515109
Self-citationSemaglutide: Scoping Review with ☸️SAIMSARA
SAIMSARA (2026) · SAIMSARA Journal · doi:10.62487/saimsara45190890
Orale Einnahme von 25 mg Semaglutid bei Erwachsenen mit Übergewicht oder Adipositas
Finze, A., Otto, M., & Reißfelder, C. (2026) · Die Chirurgie · doi:10.1007/s00104-026-02452-x
merging Advances in Oral and Injectable Anti-Obesity Pharmacotherapies: A Review of Current Evidence
Madsbad, S. (2025) · Medical Research Archives · doi:10.18103/mra.v14i1.7208
Vafeidou, K., Koufakis, T., Stavropoulos, K., Zarfeiadou, M., Doumas, M. N., & Patoulias, D. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2634086
“Common adverse events were gastrointestinal disorders, mostly of mild to moderate intensity, and consistent with those observed with subcutaneous administration [14].”
Monnier, L., Schlienger, J.-L., & Colette, C. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.002
Bariatric surgery in the era of modern obesity pharmacotherapy
Zhao, A. Y., & Dash, S. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag004
Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2025
Andersen, C. A., Wieland, M. L., Bornstein, S. L., Huber, J. M., Sytsma, T. T., Bhuiyan, M. N., & Wingo, M. T. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.02.048
Can weight-loss pills replace injectables? What the science says
Lenharo, M. (2026) · Nature · doi:10.1038/d41586-026-00856-7
Rajan, K., Jutley, A., Holliday, M. W., & Navaneethan, S. D. (2026) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s522424
“39,40 Enhancing the Adoption of These Agents Although numerous clinical trials have shown the significant benefits of cardiovascular and renal protection for individuals with diabetes and CKD, adoption of GLP-1RA in clinical practice remains low.”
VALENZA, M. (2026) · Electronic Theses and Dissertations Repository (University of Pisa)
Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions
Hajibandeh, S., Tao, Y.-A., Hsieh, M.-H., Liu, H.-H. “., Cheng, Y.-F., Lee, K.-H., Hsieh, S.-Y., & Lu, C. (2026) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2026.103117
Pestka, J., Figiel, A., Zaborek, P., Bernad, M., Widomska, K., & Marguła, R. (2026) · Quality in Sport · doi:10.12775/qs.2026.54.70610
Agboola, F. O., Fahim, S. M., Lin, G. A., Lee, W., Richardson, M., & Rind, D. M. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.5.631 · Cited by 3
Ciudin, A., Johansson, E., Zimner‐Rapuch, S., Dimitriadis, G. K., Hempfling, M., Clark, L. J., Fan, L., & Sapin, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70773
Pineda-Wieselberg, R. J., Soares, A. H., Napoli, T. F., Scalissi, N. M., & Salles, J. E. N. (2026) · Nutrients · doi:10.3390/nu18091419
“…and six months); treatment with one of the five main pharmacological options analyzed and available in Brazil: subcutaneous and oral semaglutide [10–12], naltrexone/bupropion [13–15], sibutramine [16,17], topiramate [18], or tirzepatide [19], as the only anti-obesity medication during the six…”
InfluentialBarbosa, P. E. T., Pezzi, S. A., & de Santana, E. S. (2026) · Veredas do Direito Direito Ambiental e Desenvolvimento Sustentável · doi:10.18623/rvd.v23.6237
Finding Common Ground: Updates from ObesityWeek 2025
Millard, A. J. (2026) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2026.04.005
Prolonged Dysesthesia After Massive Accidental Semaglutide Overdose: A Case Report
Quarenghi, M., Stanga, A., & Bergamaschi, A. (2026) · Journal of the American College of Emergency Physicians Open · doi:10.1016/j.acepjo.2026.100427
The fourth controlled release society workshop on oral peptide administration
Brayden, D. J., Buckley, S. T., & Lewis, A. L. (2026) · Frontiers in Drug Delivery · doi:10.3389/fddev.2026.1860678
“Since the workshop, a higher-strength oral semaglutide of 25 mg (Wharton et al., 2025) was approved by the FDA for patients with obesity (Wegovy ® Oral), along with a second-generation Rybelsus ® (Nielsen et al., 2025) with lower semaglutide doses for patients with type II diabetes.”
Elatrebi, S. F., Abuyadek, R. M., Abdelbar, S. M. M., Ahmad, M. S., Ayyad, M., Quoritem, M. A., Majid, R. O. A., Arafat, M., Amgad, A., & Alnagar, A. (2026) · World Journal of Transplantation · doi:10.5500/wjt.120572
Castro-Gamboa, J. A., Mora-Jiménez, J., Arguedas‐Chacón, S., & Zavaleta‐Monestel, E. (2026) · Cureus · doi:10.7759/cureus.110178
Multireceptor modulation in metabolic disease: are more targets better?
Zhang, S., & Lingvay, I. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01136-0
Self-citationTreatment potential of oral small-molecule GLP-1 receptor agonists
Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01135-9
English, K. J., & Kumar, K. A. (2026) · World Journal of Methodology · doi:10.5662/wjm.121475
Orales Semaglutid zur Gewichtsreduktion
Krome, S. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2736-7896
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications
Chao, A. M., Asante, R., Sersah, M. E., Jahangir, U. A., Peary, A., & Kudaya, D. Q. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70162
Sargis, R. M., Reutrakul, S., Trasande, L., & Nadal, Á. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01635-4
“Importantly, while there are oral formulations of semaglutide [113, 114] and small molecule GLP-1R agonists in development [115], the vast majority of these revolutionary agents are administered subcutaneously mostly using single-use disposable plastic devices.”
Risk factor obesity: treatment standard
Mashayekhi, M., Qing, J., Heidari‐Bateni, G., Mathew, R. O., Liew, A., Kronbichler, A., Lerma, E. V., Abdipour, A., Codorniz, K., Wu, J., et al. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag164
“…loss over 64 weeks, with a mean reduction of 13.6% compared with 2.2% with placebo (between-group difference − 11.4 percentage points; P < .001), and significantly improved physical function and multiple cardiometabolic risk factors, including glycemia, lipids, and inflammatory markers [ 21 ].”
InfluentialXu, R., Chang, Y., Su, E., Wang, Y., Zhang, Y., Ma, X., Han, X., & Zhu, R. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1853598
“However, they are frequently associated with gastrointestinal adverse effects, with reported rates as high as 72.5% (7, 8), and require subcutaneous administration, which may compromise adherence (9).”
InfluentialPagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
Laffin, L. J., Schlaich, M. P., Hall, M. E., Xie, C. C., Rao, G. S., Rettiganti, M., Dennehy, E. B., & Linetzky, B. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101783
“The BMI inclusion criterion of ≥ 25 kg/m² follows the definition outlined by World Health Organization (WHO) [4], and is lower than the ≥ 27 kg/m² commonly applied in chronic weight management studies, which additionally require at least one weight-related comorbidity [30, 36,37] .”
Metadata
- Authors
- Wharton, S., Lingvay, I., Bogdanski, P., Duque do Vale, R., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T.
- Affiliations
- University of Toronto (CA)
- The University of Texas Southwestern Medical Center (US)
- Department of Treatment of Obesity, Metabolic Disorders, and Clinical Dietetics, Poznań University of Medical Sciences, Poznań, Poland
- Novo Nordisk, Søborg, Denmark
- Department of Internal Medicine, Endocrinology, and Diabetology, Cardiometabolic Institute, Villingen-Schwenningen, Germany
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk (India) (IN)
- Washington Center for Weight Management and Research (US)
- University of Alabama at Birmingham (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-09-18
- Volume
- 393
- Issue
- 11
- Pages
- 1077-1087
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4414160143
- Cited by
- 142
- References
- 12
- Citations by year
- 2026: 127 · 2025: 15
- FWCI
- 79.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- oral semaglutide, obesity, overweight, weight loss, GLP-1 receptor agonists, gastrointestinal adverse effects, lifestyle intervention, obesity-related comorbidities, non-diabetic adults, weight regain after weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Life Style, Male, Middle Aged, Obesity, Quality of Life, Weight Loss, Body Mass Index, Treatment Outcome, Anti-Obesity Agents, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.